Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer

J Li, L Li, P You, Y Wei, B Xu - Seminars in Cancer Biology, 2023 - Elsevier
Esophageal cancer is a unique and complex heterogeneous malignancy, with substantial
tumor heterogeneity: at the cellular levels, tumors are composed of tumor and stromal …

Tackling neurodegeneration in vitro with omics: a path towards new targets and drugs

C Carraro, JV Montgomery, J Klimmt… - Frontiers in Molecular …, 2024 - frontiersin.org
Drug discovery is a generally inefficient and capital-intensive process. For
neurodegenerative diseases (NDDs), the development of novel therapeutics is particularly …

Identification of drug candidates targeting monocyte reprogramming in people living with HIV

R Knoll, L Bonaguro, JC Dos Santos… - Frontiers in …, 2023 - frontiersin.org
Introduction People living with HIV (PLHIV) are characterized by functional reprogramming
of innate immune cells even after long-term antiretroviral therapy (ART). In order to assess …

Unleashing the potential of cell painting assays for compound activities and hazards prediction

F Odje, D Meijer, E Von Coburg… - Frontiers in …, 2024 - frontiersin.org
The cell painting (CP) assay has emerged as a potent imaging-based high-throughput
phenotypic profiling (HTPP) tool that provides comprehensive input data for in silico …

Drug Mechanism: A bioinformatic update

M Cirinciani, E Da Pozzo, ML Trincavelli… - Biochemical …, 2024 - Elsevier
A drug Mechanism of Action (MoA) is a complex biological phenomenon that describes how
a bioactive compound produces a pharmacological effect. The complete knowledge of MoA …

Cost-Effective Transcriptomic Drug Screening — Unlocking New Targets (Video)| JoVE

J Leidner, H Theis, M Kraut, A Ragogna… - JoVE (Journal of …, 2024 - jove.com
Transcriptomics allows to obtain comprehensive insights into cellular programs and their
responses to perturbations. Despite a significant decrease in the costs of library production …

High-Grade Serous Ovarian Cancer Drug Development: Investigating the mechanism of action of PLK1 and BRD4 inhibitors in HGSOC

A Pociute - 2024 - cronfa.swan.ac.uk
Background. In females, ovarian cancer is the 5th cancer-related death cause and the
deadliest gynaecological cancer. High-grade serous ovarian cancer accounts for the …